Grifols to Work With FDA, Collect Plasma From Covid-19 Patients

March 25, 2020, 8:21 PM

Grifols enters formal collaboration with the U.S. Biomedical Advanced Research Development Authority (BARDA) and FDA to collect plasma from convalescent Covid-19 patients.

  • Will process plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat Covid-19
  • In Spain, Grifols is working on a clinical test with inactivated plasma from recovered patients through a collaboration with donation centers, public hospitals
  • Grifols comments in regulatory statement

To contact the reporter on this story:
Macarena Munoz in Madrid at mmunoz39@bloomberg.net

To contact the editors responsible for this story:
Beth Mellor at bmellor@bloomberg.net

Jim Silver

© 2020 Bloomberg L.P. All rights reserved. Used with permission.

To read more articles log in. To learn more about a subscription click here.